Seelos Therapeutics Shares Spike Higher; Co Confirms Earlier Report To Acquire Exclusive License Of iX Biopharma’s Proprietary Wafer-Based Delivery Platform For Sublingual Ketamine For Upfront Fee Of $9M
by | Nov 24, 2021 | Extra Jobs | 0 comments
by | Nov 24, 2021 | Extra Jobs | 0 comments
Recent Comments